ID
13521
Beschreibung
Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible; ODM derived from: https://clinicaltrials.gov/show/NCT01361334 Principal Investigator: PD Dr. Torsten Kessler, University Hospital Muenster, Germany
Link
https://clinicaltrials.gov/show/NCT01361334
Stichworte
Versionen (6)
- 11.04.13 11.04.13 - Martin Dugas
- 26.07.13 26.07.13 - Martin Dugas
- 20.04.14 20.04.14 - Julian Varghese
- 18.08.15 18.08.15 - Martin Dugas
- 14.01.16 14.01.16 -
- 11.02.16 11.02.16 -
Hochgeladen am
11. Februar 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Acute Myeloid Leukemia NCT01361334
Eligibility Acute Myeloid Leukemia NCT01361334
- StudyEvent: Eligibility
Beschreibung
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Beschreibung
1. patients with a valid option for intensive chemotherapy and/or stem cell transplantation (patients after allogeneic stem cell transplant must be off immunosuppressive agents for at least 2 weeks prior to study entry and graft-versus host disease must have resolved to grade ≤2)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0683525
- UMLS CUI [1,2]
- C1504389
- UMLS CUI [1,3]
- C0392920
Beschreibung
2. history of cancer that according to the investigator might confound the assessment of the endpoints of the study
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C2735088
- UMLS CUI [1,2]
- C0006826
Beschreibung
3. uncontrolled peptic ulcer disease or clinically significant gastrointestinal abnormalities which interfere with oral dosing or any unstable or serious concurrent condition (e.g., active uncontrolled infection)
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0030920
Beschreibung
4. poorly controlled hypertension [defined as systolic blood pressure (sbp) of ≥140 mmhg or diastolic blood pressure (dbp) of ≥90 mmhg]. note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. bp must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) sbp / dbp values from each bp assessment must be <140/90 mmhg in order for a subject to be eligible for the study
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1868885
- UMLS CUI [1,2]
- C0020538
Beschreibung
5. prolongation of corrected qt interval (qtc) >480 milliseconds
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0489625
Beschreibung
6. history of any one of more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, class iii or iv congestive heart failure, as defined by the new york heart association (nyha)
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0010068
- UMLS CUI [2]
- C0085096
- UMLS CUI [3]
- C0018802
Beschreibung
7. history of cerebrovascular infarction or bleeding, pulmonary embolism, or untreated deep venous thrombosis (dvt) within the past 6 months. note: subjects with recent dvt who have been treated with therapeutic anti-coagulant agents for at least 6 weeks are eligible
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0007785
- UMLS CUI [2]
- C2937358
- UMLS CUI [3]
- C0034065
- UMLS CUI [4]
- C0149871
Beschreibung
8. evidence of serious active bleeding or bleeding diathesis (except for bleeding or petechiae due to aml-related thrombocytopenia which will be treated using platelet transfusions). also, patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels will be excluded from the study due to excess risk of bleeding.
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1458140
Beschreibung
9. prior major surgery or trauma within 28 days prior to first dose of study drug
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0679637
- UMLS CUI [2]
- C3263723
Beschreibung
10. treatment with an investigational agent within 28 days or 5 half-lives, whichever is longer prior to the first dose of study drug (for bevacizumab 60 days).
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0013230
Beschreibung
11. concurrent cytoreductive chemotherapy (hydroxyurea must be discontinued at least one day before start of study medication)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0392920
- UMLS CUI [1,2]
- C0205420
Beschreibung
12. known immediate or delayed hypersensitivity reaction or idiosyncrasy to pazopanib
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C1831796
Beschreibung
13. patients with psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0376405
Beschreibung
14. pregnant or lactating and actively breastfeeding patients
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0549206
- UMLS CUI [2]
- C0006147
Beschreibung
15. patients taking any of the following prohibited medication: clarithromycin, telithromycin, troleandomycin (antibiotics)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C0013227
- UMLS CUI [1,3]
- C0055856
- UMLS CUI [1,4]
- C0907410
- UMLS CUI [1,5]
- C0041165
Beschreibung
ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (hiv protease inhibitors)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C0013227
- UMLS CUI [1,3]
- C0754188
- UMLS CUI [2]
- C0525005
- UMLS CUI [3]
- C0286738
- UMLS CUI [4]
- C0292818
Beschreibung
itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C0013227
- UMLS CUI [1,3]
- C0022625
- UMLS CUI [2]
- C0064113
- UMLS CUI [3]
- C0016277
Beschreibung
nefazodone (antidepressant)
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0683610
- UMLS CUI [1,2]
- C0013227
- UMLS CUI [1,3]
- C0068485
Ähnliche Modelle
Eligibility Acute Myeloid Leukemia NCT01361334
- StudyEvent: Eligibility
C0205269 (UMLS CUI [1,2])
C0278780 (UMLS CUI [1,3])
C1554961 (UMLS CUI [2,1])
C0023487 (UMLS CUI [2,2])
C1982687 (UMLS CUI [1,2])
C0205411 (UMLS CUI [1,2])
C1504389 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0006826 (UMLS CUI [1,2])
C0020538 (UMLS CUI [1,2])
C0085096 (UMLS CUI [2])
C0018802 (UMLS CUI [3])
C2937358 (UMLS CUI [2])
C0034065 (UMLS CUI [3])
C0149871 (UMLS CUI [4])
C3263723 (UMLS CUI [2])
C0205420 (UMLS CUI [1,2])
C1831796 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0013227 (UMLS CUI [1,2])
C0055856 (UMLS CUI [1,3])
C0907410 (UMLS CUI [1,4])
C0041165 (UMLS CUI [1,5])
C0013227 (UMLS CUI [1,2])
C0754188 (UMLS CUI [1,3])
C0525005 (UMLS CUI [2])
C0286738 (UMLS CUI [3])
C0292818 (UMLS CUI [4])
C0013227 (UMLS CUI [1,2])
C0022625 (UMLS CUI [1,3])
C0064113 (UMLS CUI [2])
C0016277 (UMLS CUI [3])
C0013227 (UMLS CUI [1,2])
C0068485 (UMLS CUI [1,3])